We recently published a list of The Best and Worst Dow Stocks for the Next 12 Months. In this article, we are going to take a ...

Amgen (NASDAQ:AMGN) is set to report its Q1 earnings results on Thursday, May 1st, after the market closes. Street ...

Key growth drivers include major biologics' patent expirations and cost-effectiveness, while European market leads with 45.8% share in 2023.Dublin, April 30, 2025 (GLOBE NEWSWIRE) -- The "Biosimilars: ...

Burling Wealth Partners LLC added 929 shares of Amgen to its portfolio in Q4, worth about $242,000—a modest but calculated ...

The Hormone Replacement Therapy Market is estimated to grow at a CAGR of 6.48% during the forecast period from 2024 to 2030.

Consumer staples like Coca-Cola as well as healthcare and industrial stocks should hold up well. But don’t abandon tech just ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vigil Neuroscience, Inc.’s VIGL share price has surged by 5.73%, which has investors questioning if this is right time to ...

While pharma manufacturing deals in the US increased, large cuts to research and regulatory agencies increased concerns for the sector.

Brian Lortie, president and CEO at Uniquity Bio, offered up key insights on building teams, securing capital, and operating with efficiency during a recent Business of Biotech podcast recording.

A good performance from generics was driven by the successful recent launch of paclitaxel, as well as continued strong growth in Canada. Biosimilar net-sales growth would have been positive when ...

April was a month of rapid escalation and partial de-escalation, driving major moves across equity, bond, and commodity ...